Description
An orally bioavailable positive allosteric modulator of mGluR4 (EC50 = 1 µM); has a greater than 30-fold selectivity for mGluR4 over mGluR5 in vitro; has no activity at concentrations up to 10 µM at A2A, 5-HT1A, or α2A-adrenergic receptors; reduces catalepsy in a haloperidol-induced catalepsy rat model of Parkinson’s disease (ED50 = ~1 mg/kg); leads to downregulation of GRM4 and GABRA1 in rat brain without affecting hippocampal-dependent memory
Formal name: (E)-4-(2-phenylethenyl)-2-pyrimidinamine
Synonyms:
Molecular weight: 197.2
CAS: 125404-04-8
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology|Allosteric Modulators||Research Area|Neuroscience|Neurodegenerative Disorders|Parkinson’s Disease